fluticasone


Also found in: Medical, Acronyms, Wikipedia.
Translations

fluticasone

n fluticasona
References in periodicals archive ?
The closed triple combination therapy comprises three medicines: fluticasone furoate, an inhaled corticosteroid (ICS), umeclidinium, a long-acting muscarinic antagonist (LAMA) and vilanterol, a long-acting beta2-adrenergic agonist (LABA), delivered once-daily in GSK's Ellipta dry powder inhaler.
Patients received 100 meg of fluticasone furoate and 25 meg of vilanterol or usual care.
At the end of run-in period, the baseline symptoms and signs of asthma, PFT, amount of rescue medication and nocturnal awakening due to asthma symptoms were recorded and Accuhaler with fluticasone 100 micrograms and salmeterol 50 micrograms applied.
GlaxoSmithKline has proposed that two fixed-dose combinations, 100 mcg or 200 mcg of the inhaled corticosteroid (ICS) fluticasone with 25 mcg of the long-acting beta-agonist (LABA) vilanterol in a dry powder inhaler, be approved for maintenance treatment of asthma in patients age 12 years and older, administered once per day.
During the run-in period patients received fluticasone propionate 250 [micro]g twice daily, patients whose asthma was well controlled after 4 weeks of initial treatment were assigned for the study.
The study also shored a fast onset compared to placebo, as well as more rapid relief and greater response rate compared to either fluticasone and azelastine alone, or placebo.
The FP/FORM combination brings together the attributes of the two compounds: fluticasone propionate, the most widely prescribed inhaled corticosteroid in Europe*and formoterol fumarate, a long-acting beta2-agonist characterised by a fast onset of action.
On prescribed inhaled fluticasone 50 [micro]g and salmeterol he developed facial and truncal obesity, a buffalo hump and facial hirsuitism within 2 months.
Fluticasone was administered at dosages of 44 mcg, 110 mcg or 220 mcg administered every 12 hours to six cats.
In the second study, high-dose inhaled fluticasone, given at the first sign of an upper respiratory tract infection to prevent wheezing recurrences, did improve symptoms but appeared to impair normal growth in a study of 129 patients.
The researchers noted a 20 percent reduction in the duration of the illness and also found that children who had received fluticasone had milder symptoms of shorter duration compared with the placebo group, thereby reducing the impact of the disease on the parents' quality of life.
The patient was aggressively treated for laryngopharyngeal reflux and allergy with esomeprazole, nizatidine, montelukast sodium, and fluticasone.